ArticleAntioxidants & redox signaling2016
Targeted Nitric Oxide Delivery by Supramolecular Nanofibers for the Prevention of Restenosis After Arterial Injury.
Article in Antioxidants & redox signaling, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 57 citations in OpenAlex.
- Nitric Oxide in Biomaterial-Based Therapies for Coronary Heart Disease: Mechanistic Insights, Current Advances, and Translational Prospects.Biomaterials research · 2025Review
- The Impact of Helium and Nitrogen Plasmas on Electrospun Gelatin Nanofiber Scaffolds for Skin Tissue Engineering Applications.Journal of functional biomaterials · 2024Article
- An Integrated Arterial Remodeling Hydrogel for Preventing Restenosis After Angioplasty.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Nanomedicines for cardiovascular disease.Nature cardiovascular research · 2023Review
- Peptide Amphiphile Supramolecular Nanofibers Designed to Target Abdominal Aortic Aneurysms.ACS nano · 2022Article
- Antioxidant Response Activating nanoParticles (ARAPas) localize to atherosclerotic plaque and locally activate the Nrf2 pathway.Biomaterials science · 2022Article
- Biomimetic, ROS-detonable nanoclusters - A multimodal nanoplatform for anti-restenotic therapy.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Development of novel nanofibers targeted to smoke-injured lungs.Biomaterials · 2021Article
- Evaluation of a Targeted Drug-Eluting Intravascular Nanotherapy to Prevent Neointimal Hyperplasia in an Atherosclerotic Rat Model.Advanced nanobiomed research · 2021Article
- Intravenous Delivery of Lung-Targeted Nanofibers for Pulmonary Hypertension in Mice.Advanced healthcare materials · 2021Article
- Light sheet fluorescence microscopy as a new method for unbiased three-dimensional analysis of vascular injury.Cardiovascular research · 2021Article
- HExperimental biology and medicine (Maywood, N.J.) · 2021Article
- Identification of Novel Biomarkers for Pre-diabetic Diagnosis Using a Combinational Approach.Frontiers in endocrinology · 2021Article
- Design of materials with supramolecular polymers.Progress in polymer science · 2020Review
- Pharmacokinetics and biodistribution of a collagen-targeted peptide amphiphile for cardiovascular applications.Pharmacology research & perspectives · 2020Article
- Development of Optimized Tissue-Factor-Targeted Peptide Amphiphile Nanofibers to Slow Noncompressible Torso Hemorrhage.ACS nano · 2020Article
- Stab2-Mediated Clearance of Supramolecular Polymer Nanoparticles in Zebrafish Embryos.Biomacromolecules · 2020Article
- Diabetic vasculopathy: macro and microvascular injury.Current pathobiology reports · 2020Article
- Development of Fractalkine-Targeted Nanofibers that Localize to Sites of Arterial Injury.Nanomaterials (Basel, Switzerland) · 2020Article
- Self-assembled peptide nanostructures targeting death receptor 5 and encapsulating paclitaxel as a multifunctional cancer therapy.ACS biomaterials science & engineering · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
aimsCardiovascular interventions continue to fail as a result of arterial restenosis secondary to neointimal hyperplasia. We sought to develop and evaluate a systemically delivered nanostructure targeted to the site of arterial injury to prevent neointimal hyperplasia. Nanostructures were based on self-assembling biodegradable molecules known as peptide amphiphiles. The targeting motif was a collagen-binding peptide, and the therapeutic moiety was added by S-nitrosylation of cysteine residues.
resultsStructure of the nanofibers was characterized by transmission electron microscopy and small-angle X-ray scattering. S-nitrosylation was confirmed by mass spectrometry, and nitric oxide (NO) release was assessed electrochemically and by chemiluminescent detection. The balloon carotid artery injury model was performed on 10-week-old male Sprague-Dawley rats. Immediately after injury, nanofibers were administered systemically via tail vein injection. S-nitrosylated (S-nitrosyl [SNO])-targeted nanofibers significantly reduced neointimal hyperplasia 2 weeks and 7 months following balloon angioplasty, with no change in inflammation. INNOVATION: This is the first time that an S-nitrosothiol (RSNO)-based therapeutic was shown to have targeted local effects after systemic administration. This approach, combining supramolecular nanostructures with a therapeutic NO-based payload and a targeting moiety, overcomes the limitations of delivering NO to a site of interest, avoiding undesirable systemic side effects.
conclusionWe successfully synthesized and characterized an RSNO-based therapy that when administered systemically, targets directly to the site of vascular injury. By integrating therapeutic and targeting chemistries, these targeted SNO nanofibers provided durable inhibition of neointimal hyperplasia in vivo and show great potential as a platform to treat cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.